Long-Term Analysis of Phase 3 Head-To-Head Study Confirms KYPROLIS® (Carfilzomib) Regimen Extends Overall Survival in Patients with Relapsed Multiple Myeloma News Release
http://www.ono.co.jp/eng/news/pdf/sm_cn170901_2.pdf
More from tokioX :
- 💊Karyopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Penta-Refractory Multiple Myeloma
- 💊Opdivo Plus Yervoy Combination Delivered Overall Survival Benefit Across PD-L1 Expression Levels in Intermediate- and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
- ono、Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival and Showed Durable Responses in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
- Two important clinical trials of Ono Pharmaceuticals, Opivo® (generic name: niborumab) demonstrate the benefits of three-year survival in patients 20170911
- Ono and Seikagaku Reach a Definitive Agreement Related to Co-development and Marketing Collaboration on SI-613 for the Treatment of Osteoarthritis in Japan News Release 20170901
- Opdivo® (Nivolumab) Intravenous Infusion Approved for Supplemental Indications of Advanced Renal Cell Carcinoma, Relapsed or Progressed Classical Hodgkin Lymphoma, Recurrent or Metastatic Head and Neck, Locally Advanced or Metastatic Urothelial Carcinoma, and Unresectable or Metastatic Melanoma in Combination with Ipilimumab in South Korea News Release 20170830
- 小野薬品、再発の多発性骨髄腫患者を対象とした第III相試験においてKyprolis®（カルフィルゾミブ）の併用療法が有意に全生存期間の延長を示す ( Second Phase III Study Shows Kyprolis® (Carfilzomib) Regimen Significantly Improves Overall Survival in Patients with Relapsed Multiple Myeloma ）